 Source: rafapress Shutterstock.com Crispr Therapeutics NASDAQ: CRSP stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel exa-cel a rolling review. That rolling review starts in November and covers the use of exa-cel in treating SCD and TDT. 